<u>REQUEST FOR NAMES, EMAILS, AND ADDRESSES OF SETTLEMENT CLASS MEMBERS</u>
STRATEGIC CLAIMS SERVICES
600 N. JACKSON STREET, SUITE 205
MEDIA, PA 19063
PHONE: (610) 565-9202 EMAIL: info@strategicclaims.net FAX: (610) 565-7985

September 15, 2026

This letter is being sent to all entities whose names have been made available to us, or which we believe may know of potential Settlement Class Members.

We request that you assist us in identifying any individuals/entities who fit the following description, whether or not the beneficial owner/purchaser has enrolled in a claim-filing program with their broker or financial institution:

ALL PERSONS AND ENTITIES THAT PURCHASED OR OTHERWISE ACQUIRED KIROMIC BIOPHARMA, INC. ("KIROMIC" or the "COMPANY") COMMON STOCK: (1) PURSUANT AND/OR TRACEABLE TO THE OFFERING DOCUMENTS AND/OR (2) BETWEEN JUNE 25, 2021 AND FEBRUARY 2, 2022, BOTH DATES INCLUSIVE, AND SUBJECT TO 15 U.S.C. § 78U-4(E)(1) (the "CLASS PERIOD").

Excluded from the Settlement Class are: (i) the Defendants; (ii) the officers and directors of the Company at all relevant times; (iii) members of any Individual Defendant's immediate families; (iv) any entity in which any of the Defendants have or had a controlling interest or which is related to or affiliated with any of the Defendants; (v) the legal representatives, heirs, successors, and assigns of such excluded Persons; (vi) those who purchased or otherwise acquired Kiromic common stock on foreign exchanges, in accordance with the United States Supreme Court's decision in *Morrison v. Nat'l Australia Bank Ltd.*, 561 U.S. 247, 267 (2010); (vii) the plaintiffs in *Sabby Volatility Warrant Master Fund Ltd., et al. v. Kiromic Biopharma, Inc.*, No. 22-cv-1927(AT) (S.D.N.Y.), and any claims that were or could have been filed or consolidated therewith.

The information below may assist you in finding the above requested information:

Kiromic BioPharma, Inc., Securities Litigation Case No.: 1:22-cv-06690 (JHR) Objection Deadline: November 12, 2026 Exclusion Deadline: November 26, 2026 Notice to Appear Deadline: November 26, 2026 Claim Filing Deadline: December 14, 2026 Fairness Hearing: December 17, 2026	**Security Identifiers:** • CUSIP: 497634105 (during the Class Period) • ISIN: US4976341051 (during the Class Period) • SEDOL: BMCRRM3 (during the Class Period) • Ticker Symbol: NASDAQ: KRBP (during the Class Period) • CUSIP: 497634204 (current) • ISIN: US4976342042 (current) • Ticker Symbol: OTC: KRBPQ (current)

<u>PER COURT ORDER, PLEASE RESPOND WITHIN 10 CALENDAR DAYS FROM THE DATE OF THIS NOTICE.</u>

Please comply in one of the following ways:

1. If you have no beneficial purchasers/owners, please advise us in writing; or
2. **Supply us with names, last known addresses, and email addresses (to the extent available)** of your beneficial purchasers/owners and we will do the emailing of the link to the location of the Notice of Pendency and Proposed Settlement of Class Action, Fairness Hearing and Class Members's Rights and the Proof of Claim and Release Form (collectively the "Notice and Proof of Claim") or mailing of the Postcard Notice. Please provide us this information electronically; or
3. Advise us of how many beneficial purchasers/owners you have, and we will supply you with ample postcards to do the mailing. After the receipt of the Postcard Notices, you have ten (10) calendar days to mail them; or
4. Use the link below to the location of the Notice and Proof of Claim and email the link to each of your beneficial purchasers/owners within ten (10) calendar days after receipt thereof.

You can bill us for any reasonable expenses actually incurred and **not to exceed**:

- **$0.03 per link to the location of the Notice and Proof of Claim emailed,** OR
- **$0.03 per name, address, and email address (to the extent available)** if you are providing us the records, OR
- **$0.03 per name and address, including materials, plus postage at the pre-sort rate used by the Claims Administrator** if you are requesting the Postcard Notices and performing the mailing.

Please use the following direct link to the electronic Notice and Proof of Claim for emails: https://www.strategicclaims.net/wp-content/uploads/2026/09/Final-Kiromic-Notice-and-Proof-of-Claim-and-Release-Form.pdf

All invoices must be received within 30 days of this letter.

You are on record as having been notified of the legal matter. A copy of the Notice and Proof of Claim and other important case-related documents are available on our website at www.strategicclaims.net/Kiromic/. You can also request a copy via email at info@strategicclaims.net.

Thank you for your prompt response.

Regards,

Claims Administrator
Kiromic BioPharma, Inc., Securities Litigation

PLEASE NOTE - A COPY OF THE POSTCARD NOTICE IS ON THE REVERSE SIDE OF THIS LETTER.

Kiromic BioPharma, Inc., Securities Litigation
c/o Strategic Claims Services
600 N Jackson St., Ste. 205
Media, PA 19063

In re Kiromic BioPharma, Inc. Securities Litigation Case No. 1:22-cv-06690 (JHR) Case Pending in U.S. District Court for the Southern District of New York **Court-Ordered Legal Notice** **Forwarding Service Requested** *Important Notice about a Securities Class Action Settlement* *You may be entitled to a payment.* *This Notice may affect your legal rights.* *Please read it carefully.*	Kiromic BioPharma, Inc. Securities Litigation c/o Strategic Claims Services 600 N. Jackson Street, Ste. 205 Media, PA 19063

The U.S. District Court for the Southern District of New York (the "Court") has preliminarily approved a proposed Settlement of claims against Maurizio Chiriva Internati, Tony Tontat, Gianluca Rotino, Pietro Bersani, Americo Cicchetti, Michael Nagel, Jerry Schneider, Kiromic BioPharma, Inc. ("Kiromic," collectively, the "Kiromic Defendants"). The proposed Settlement would resolve a class action lawsuit against that the Kiromic Defendants only, which alleged the Kiromic Defendants made false and/or misleading misstatements and/or omissions in certain of Kiromic's offering documents concerning the status of Kiromic's investigational new drug applications. The Kiromic Defendants deny the allegations.[1]

You received this notice because you may have purchased or acquired (a) Kiromic common stock pursuant and/or traceable to the Offering Documents (defined in the Settlement) and/or (b) Kiromic common stock between June 25, 2021 and February 2, 2022, both dates inclusive and subject to 15 U.S.C. § 78u-4(e)(1), and you may be a Settlement Class Member. The Settlement provides that, in exchange for dismissal and release of claims against the Kiromic Defendants, a fund consisting of $1,225,000, less attorneys' fees and expenses, will be divided among Settlement Class Members who timely submit valid Proof of Claim and Release Forms ("Proof of Claim") if the Court grants final approval of the Settlement. Plaintiffs believe that the proposed Settlement is fair, reasonable and in the best interests of the Settlement Class. For a full description of the Settlement and your rights and to make a claim, please view the Stipulation of Settlement and obtain a copy of the Notice of Pendency and Proposed Settlement of Class Action, Fairness Hearing and Class Members Rights' ("Notice") and Proof of Claim by visiting the website: www.strategicclaims.net/Kiromic/ (the "Website"). You may request copies of the Notice and Proof of Claim by contacting the Claims Administrator by: (1) mail: Kiromic BioPharma, Inc. Securities Litigation, c/o Strategic Claims Services, 600 N. Jackson St., Ste. 205, P.O. Box 230, Media, PA 19063; (2) call toll-free: 1-866-274-4004; or (3) email: info@strategicclaims.net.

To qualify for payment, you must submit a Proof of Claim to the Claims Administrator, which can be found on the Website. PROOF OF CLAIM FORMS MUST BE POSTMARKED BY DECEMBER 14, 2026 and should be mailed to the address above or submitted electronically by December 14, 2026 at 11:59 p.m. through the Website. If you do not want to be legally bound by the Settlement, you must exclude yourself postmarked no later than November 26, 2026. If you exclude yourself, you cannot get money from this Settlement. If you stay in the Settlement, you may object to it by November 12, 2026. The Notice explains how to exclude yourself or to object.

The Court will hold a hearing in this case on December 17, 2026 at 11:45 a.m. at the United States District Court for the Southern District of New York, Daniel Patrick Moynihan United States Courthouse, 500 Pearl St. Courtroom 12B, New York, NY 10007, to consider whether to approve the Settlement, the Plan of Allocation, and a request by Lead Counsel for no more than 33 1/3% of the Settlement Fund for their attorneys' fees, expenses, and Awards to Plaintiffs. You may, but do not have to, attend the hearing and ask to be heard by the Court. The Court reserves the right to hold the Settlement Hearing telephonically or by other virtual means.

[1] For the avoidance of doubt, the claims against ThinkEquity are not being resolved by this Settlement and will continue.